A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy

Ganz, 2012, National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer, Ann Intern Med, 156, 591, 10.7326/0003-4819-156-8-201204170-00010 Wilt, 2010, Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, 367, 203, 10.1056/NEJMoa1113162 Stattin, 2012, Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study, J Natl Cancer Inst, 102, 950, 10.1093/jnci/djq154 Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 Cooperberg, 2010, Time trends and local variation in primary treatment of localized prostate cancer, J Clin Oncol, 28, 1117, 10.1200/JCO.2009.26.0133 Raldow, 2012, The relationship between clinical benefit and receipt of curative therapy for prostate cancer, Arch Intern Med, 172, 362, 10.1001/archinternmed.2011.1494 Swisher-McClure, 2012, Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer, Int J Radiat Oncol Biol Phys, 83, 8, 10.1016/j.ijrobp.2011.06.1951 Mohler, 2010, NCCN clinical practice guidelines in oncology: prostate cancer, J Natl Compr Canc Netw, 8, 162, 10.6004/jnccn.2010.0012 Reese, 2012, Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system, Urology, 80, 1075, 10.1016/j.urology.2012.07.040 Stark, 2009, Gleason score and lethal prostate cancer: does 3+4=4+3?, J Clin Oncol, 27, 3459, 10.1200/JCO.2008.20.4669 Zumsteg, 2013, Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy, Int J Radiat Oncol Biol Phys, 85, 1012, 10.1016/j.ijrobp.2012.07.2374 D’Amico, 2004, Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease, J Clin Oncol, 22, 3726, 10.1200/JCO.2004.01.164 Nguyen, 2009, Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors, Int J Radiat Oncol Biol Phys, 73, 659, 10.1016/j.ijrobp.2008.05.009 Zelefsky, 1998, Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer, Int J Radiat Oncol Biol Phys, 41, 491, 10.1016/S0360-3016(98)00091-1 Zumsteg, 2012, Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?, Lancet Oncol, 13, e259, 10.1016/S1470-2045(12)70084-0 Alicikus, 2011, Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer, Cancer, 117, 1429, 10.1002/cncr.25467 Fine, 1999, A proportional hazards model for the sub distribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Jones, 2011, Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 365, 107, 10.1056/NEJMoa1012348 D’Amico, 2008, Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial, JAMA, 299, 289, 10.1001/jama.299.3.289 Valicenti, 2011, Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06, Int J Radiat Oncol Biol Phys, 79, 1323, 10.1016/j.ijrobp.2010.01.009 Krauss, 2011, Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer, Int J Radiat Oncol Biol Phys, 80, 1064, 10.1016/j.ijrobp.2010.04.004 Castle, 2013, Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?, Int J Radiat Oncol Biol Phys, 85, 693, 10.1016/j.ijrobp.2012.06.030 Shahinian, 2005, Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 352, 154, 10.1056/NEJMoa041943 Keating, 2006, Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J Clin Oncol, 24, 4448, 10.1200/JCO.2006.06.2497 Sanda, 2008, Quality of life and satisfaction with outcome among prostate-cancer survivors, N Engl J Med, 358, 1250, 10.1056/NEJMoa074311 Albertsen, 2005, Prostate cancer and the Will Rogers phenomenon, J Natl Cancer Inst, 97, 1248, 10.1093/jnci/dji248 Gallina, 2008, Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer, BJU Int, 101, 1513, 10.1111/j.1464-410X.2008.07519.x Epstein, 2005, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, Am J Surg Pathol, 29, 1228, 10.1097/01.pas.0000173646.99337.b1 Dong, 2010, Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system, Am J Surg Pathol, 36, 838, 10.1097/PAS.0b013e3182486faf Zelefsky, 2011, Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes, Eur Urol, 60, 1133, 10.1016/j.eururo.2011.08.029 Kattan, 2003, Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer, J Clin Oncol, 21, 4568, 10.1200/JCO.2003.05.046 Ingram, 2010, Risk grouping versus risk continuum in patients with clinically localized prostate cancer: a taxometric test, J Urol, 184, 1937, 10.1016/j.juro.2010.06.110